BINV Stock Overview
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 39.40 |
| 52 Week High | SEK 45.40 |
| 52 Week Low | SEK 14.00 |
| Beta | 0.39 |
| 11 Month Change | -3.08% |
| 3 Month Change | 17.44% |
| 1 Year Change | 145.33% |
| 33 Year Change | -16.70% |
| 5 Year Change | 19.03% |
| Change since IPO | -97.03% |
Recent News & Updates
Recent updates
Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?
Aug 16
We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully
Apr 09Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth
Sep 01Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive
Jun 02Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week
Feb 25We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely
Sep 28Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook
Aug 31Shareholder Returns
| BINV | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -1.9% | 0.7% | 1.1% |
| 1Y | 145.3% | 24.7% | 21.0% |
Return vs Industry: BINV exceeded the Swedish Biotechs industry which returned 22.7% over the past year.
Return vs Market: BINV exceeded the Swedish Market which returned 21.8% over the past year.
Price Volatility
| BINV volatility | |
|---|---|
| BINV Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: BINV has not had significant price volatility in the past 3 months.
Volatility Over Time: BINV's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 109 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
BioInvent International AB (publ) Fundamentals Summary
| BINV fundamental statistics | |
|---|---|
| Market cap | SEK 2.59b |
| Earnings (TTM) | -SEK 334.52m |
| Revenue (TTM) | SEK 61.15m |
42.4x
P/S Ratio-7.8x
P/E RatioIs BINV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BINV income statement (TTM) | |
|---|---|
| Revenue | SEK 61.15m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 61.15m |
| Other Expenses | SEK 395.67m |
| Earnings | -SEK 334.52m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -5.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | -547.02% |
| Debt/Equity Ratio | 0% |
How did BINV perform over the long term?
See historical performance and comparison